Mestinon (Pyridostigmine Bromide)

Pyridostigmine bromide blocks the enzyme acetylcholinesterase, which normally breaks down acetylcholine. By inhibiting this enzyme, the drug raises acetylcholine concentrations in the synaptic cleft, enhancing cholinergic signaling and improving muscle contraction where acetylcholine is deficient.

The dosage of Mestinon is individualized. A qualified prescriber determines the appropriate amount based on the patient’s condition, severity, renal function, and response to therapy. Patients should follow the prescribing clinician’s instructions and not adjust the dose on their own.

Mestinon is classified as Pregnancy Category B, indicating no evidence of risk in animal studies and a lack of well‑controlled human studies. It may be used during pregnancy if the potential benefit justifies any potential risk. Limited data exist for breastfeeding, so clinicians weigh benefits against possible exposure to the infant.

To order Mestinon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mestinon (pyridostigmine) is a reversible, peripheral cholinesterase inhibitor with a relatively short half‑life, making it suitable for chronic conditions like myasthenia gravis. Compared with neostigmine, it has less central nervous system penetration and a longer duration of action, which can reduce dosing frequency.

Mestinon tablets should be stored at temperatures below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains tightly sealed until use.

Mestinon is taken orally, usually with water. Tablets may be swallowed whole or, if necessary, divided as directed by a healthcare professional. Dosing times are often spaced throughout the day to maintain steady acetylcholine levels.

The most serious risks include cholinergic crisis, which can cause severe muscle weakness, respiratory failure, and bradycardia, as well as bronchospasm and life‑threatening allergic reactions. Prompt medical attention is required if these symptoms develop.

Mestinon is contraindicated in patients with known hypersensitivity to pyridostigmine or any tablet excipients, those with mechanical intestinal obstruction, and individuals with severe asthma or COPD where bronchospasm could be precipitated. Clinicians should also avoid use in patients taking conflicting anticholinergic agents without careful monitoring.